SGLT2 inhibitors such as canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, and sotagliflozin are recommended (IA) for the prevention of HF and cardiovascular death and deterioration in renal function in patients with type 2 diabetes and cardiovascular disease and/or cardiovascular risk factors or chronic kidney disease. This evidence concerns the gene SLC5A2 and cardiovascular disorder.